PCSK9 brings exorbitant price, and perhaps cost-control consensus

Specialty medications have been largely free from cost controls. But the introduction of injectable proprotein convertase subtilisin/kexin 9 (PCSK9) enzyme inhibitors to manage cholesterol—and the sticker shock the drug’s price will bring to consumers—might be the impetus for the healthcare system to develop consensus about the pricing of specialty medications, according to a post on the Health Affairs blog.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup